UVADEX

Active Ingredient(s): Methoxsalen
FDA Approved: * February 25, 1999
Pharm Company: * THERAKOS
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

UVADEX Overview

Methoxsalen (also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine) is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10mg tablets, which are taken in the amount of 30mg 75minutes before a PUVA (psoralen + UVA) light treatment. Le...

Read more UVADEX Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Methoxsalen

Recent UVADEX Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for UVADEX: (1 result)

Sorted by National Drug Code

• 64067-216 Uvadex 20 ug/ml Extracorporeal Injection, Solution by Therakos, Inc.

Other drugs which contain Methoxsalen or a similar ingredient: (3 results)

• 8-MOP Methoxsalen
• METHOXSALEN
• OXSORALEN-ULTRA Methoxsalen